Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
61.8M
-
Number of holders
-
74
-
Total 13F shares, excl. options
-
45.8M
-
Shares change
-
+5.94M
-
Total reported value, excl. options
-
$171M
-
Value change
-
+$22M
-
Put/Call ratio
-
0.24
-
Number of buys
-
44
-
Number of sells
-
-18
-
Price
-
$3.74
Significant Holders of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) as of Q2 2024
84 filings reported holding GLUE - Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) has 74 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45.8M shares
of 61.8M outstanding shares and own 74.18% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (7.69M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.98M shares), FMR LLC (5.09M shares), BAKER BROS. ADVISORS LP (4.92M shares), Avoro Capital Advisors LLC (4.54M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (2.66M shares), VANGUARD GROUP INC (2.55M shares), BlackRock Inc. (2.36M shares), Aisling Capital Management LP (1.47M shares), and Alphabet Inc. (1.46M shares).
This table shows the top 74 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.